Teligent, Inc. a New Jersey-based specialty generic pharmaceutical company, announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Desoximetasone Ointment USP 0.25%, the generic equivalent of Topicort® Ointment, 0.25%, of Taro Pharmaceuticals U.S.A., Inc.
This is Teligent's fourth approval from its internally developed pipeline of topical generic pharmaceutical products.
Based on recent IMS Health data from December 2015, the total addressable market for this product is approximately $17 million. Teligent originally submitted this ANDA to the FDA in November 2014.
